Biodesix Exceeds Full-Year Revenue Guidance, Affirms Q4 Adjusted EBITDA Positivity
Summary
Biodesix, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, reporting revenue that exceeded its increased guidance and affirming its expectation of positive Adjusted EBITDA for Q4 2025.
Key Events
-
Exceeded Full-Year Revenue Guidance
Preliminary full-year 2025 revenue is estimated at $88.5 million, surpassing the company's increased guidance of $84-$86 million.
-
Affirmed Q4 Adjusted EBITDA Positivity
The company affirmed its expectation of achieving positive Adjusted EBITDA for the fourth quarter of 2025, a significant profitability milestone.
-
Strong Q4 Revenue Growth
Fourth-quarter 2025 total revenue is estimated at $28.8 million, representing a 41% increase over the prior year comparable period.
-
Growth in Lung Diagnostics
Lung Diagnostics revenue grew by an estimated 47% in Q4 2025 and 22% for the full year, driven by increased test volumes and expanded reimbursement.
Analysis
The preliminary financial results indicate strong operational performance, with full-year revenue surpassing the company's raised guidance. The significant growth in Lung Diagnostics revenue and the affirmation of Adjusted EBITDA positivity in Q4 2025 are key positive indicators for the company's financial health and trajectory. This suggests improved profitability and strong demand for its diagnostic solutions, which could positively impact investor sentiment.
At the time of this filing, BDSX was trading at $9.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $78.3M. The 52-week trading range was $3.44 to $30.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.